Hello, good morning. My name is Julio Chavez. I'm from the Moffitt Cancer Center in Tampa, Florida. The study is called Long-Term Follow-Up of the Golcadomide plus Rituximab for patients with relapse refractory folliculolipoma. The rationale of the study was to test Golcadomide, which is a novel immunomodulatory drug similar to lenalidomide, which is widely used for lymphomas, for multiple myeloma. So mechanistically speaking, Golcadomide is much more potent. It's kind of like a 100% inhibition of the target. So as opposed to lenalidomide, it has like maybe 20, 25%. So there was a rationale to use this in lymphomas. And there was a pretty refractory patient population, you know, a median lines of four. Many patients had prior carotid cell therapy. Patients had bispecific antibody. So basically no really truly treatment options available for these patients. We had high response rates, almost like a kind of like a bispecific antibodies, like over response rate of almost close to 80%, CR rates of 60%. The PFS, the progression of free survival is still mature, but patients who had achieved complete response, they still have maintained response. So it's a little longer follow up, but for follicular lymphoma, we need a little bit more longer follow up to find out whether there is actually durable responses, but at least the preliminary efficacy in terms of complete responses is remarkable. Why is this study important? Because it offers an outpatient option. You know, now follicular lymphoma is being filled up with bispecific antibodies. We have two bispecific antibodies approved. We have three carotid cell therapies approved. But they're still kind of limited to academic centers or bigger hospitals in the community. They are still trying to figure out how to get these patients into the community. So this is a fully outpatient, it's oral drug. In terms of toxicities, majority of these diseases were related to neutropenia, hematology toxicity that was very well manageable with growth factors by the doctors. So I think I'm fine by all this study because how feasible is to do as an outpatient.